ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0320

Transcriptomic profiling of the skeletal muscle of knee OA patients uncovers elevated glucocorticoid and GABA signaling as mediators of skeletal muscle dysfunction in advanced disease

Gina Many1, Tyler Mansfield2, Tyler Sagendorf3, Daniel Evans2, Sameneh Farsijani4, Bret Goodpaster5, Lauren Sparks5 and NANCY LANE6, 1Pacific Northwest National Laboratory, Richland, WA, Richland, WA, 2California Pacific Medical Research Institute, San Francisco, CA, 3Pacific Northwest National Laboratory, Richland, WA, 4University of Pittsburgh, Pittsburgh, PA, 5Translational Research Institute, AventHealth, Orlando, FL, 6University of California at Davis, School of Medicine, Sacramento, CA

Meeting: ACR Convergence 2025

Keywords: Gene Expression, Osteoarthritis, pain

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0306–0336) Osteoarthritis – Clinical Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Age-related declines in muscle mass and function are leading causes for hospitalizations and mortality in elderly individuals. The risk of developing knee osteoarthritis also increases with age and those affected display reductions in skeletal muscle mass, quality and function yet the mechanisms behind these changes are broadly unknown. Characterizing the transcriptional landscape of skeletal muscle from patients with knee OA to identify molecular targets of skeletal muscle dysfunction and then formulate a targeted treatment approach.

Methods: Study participants (n=528, 56% Female; mean age 76.6 ± 4.9 years) were enrolled in the Study of Muscle, Mobility and Aging (SOMMA), a longitudinal cohort study of subjects, >70 years of age, free of life-threatening diseases and mobile. Study subjects had obtained a muscle biopsy at the baseline study visit and knee radiographs at the year 1 follow-up visit. Radiographic OA (ROA) was determined by Kellgren and Lawrence scores (0-4), and knee pain was self-reported to be at least monthly in the right knee. RNA sequencing data were analyzed using DESeq2 to assess differential gene expression, contrasting a control group (Kellgren-Lawrence (KL) score 0–1, n=322) with three nested “case” groups: (1) all KL ≥2 (n=206), (2) KL ≥2 with pain (n=114), and (3) KL ≥3 with pain (n=74). Covariates in the statistical models included sex, race/ethnicity, age, weight, waist circumference, abdominal adiposity from MRI, right anterior thigh fat free muscle volume, clinical site, batch, steps per day (using GGIR actigraph), and pain medications. Resulting pathway enrichment analysis was performed using CAMERA.

Results: DESeq2 revealed differential transcript expression across the three case-control contrasts, with 20, 10 and 22 differentially expressed genes for contrasts 1-3 respectively. Two genes, Mettl21c, a methyltransferase, and pseudogene Rpl29p11 displayed differential expression in all three contrasts. Pathway enrichment analysis revealed significant differences between the three contrasts, with gene expression regulatory terms and pathways related to ribosomes and translation being downregulated in groups 2&3. Group 3 also displayed unique enrichment of GABA secretion (z-score: 3.6, FDR=0.03) and glucocorticoid (GC) signaling (z-score: 3.4, FDR< 0.05).

Conclusion: Gene expression profiling of ROA skeletal muscle reveals differential molecular profiles based on KL grade and self-reported knee pain. Patients presenting with KL 3+ and pain displayed unique pathway enrichments indicative of transcriptional and translational repression, GC signaling and GABA secretion. Given adjustment for physical activity in statistical modeling, these findings suggests that elevated GC and GABA signaling may be potential mechanisms for skeletal muscle dysfunction and atrophy in advanced stage ROA.


Disclosures: G. Many: None; T. Mansfield: None; T. Sagendorf: None; D. Evans: None; S. Farsijani: None; B. Goodpaster: None; L. Sparks: None; N. LANE: ANI, 1.

To cite this abstract in AMA style:

Many G, Mansfield T, Sagendorf T, Evans D, Farsijani S, Goodpaster B, Sparks L, LANE N. Transcriptomic profiling of the skeletal muscle of knee OA patients uncovers elevated glucocorticoid and GABA signaling as mediators of skeletal muscle dysfunction in advanced disease [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/transcriptomic-profiling-of-the-skeletal-muscle-of-knee-oa-patients-uncovers-elevated-glucocorticoid-and-gaba-signaling-as-mediators-of-skeletal-muscle-dysfunction-in-advanced-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/transcriptomic-profiling-of-the-skeletal-muscle-of-knee-oa-patients-uncovers-elevated-glucocorticoid-and-gaba-signaling-as-mediators-of-skeletal-muscle-dysfunction-in-advanced-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology